Conditions

In part 2 of this Exclusive Interview, Dr. W. Timothy Garvey talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston, MA about the changes in medications to treat obesity as well as the treatment methods.

In part 3 of this Exclusive Interview, Dr. W. Timothy Garvey talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston, MA about the importance of good nutrition and physical activity, and which may be the more effective action.

In part 4 of this Exclusive Interview, Dr. W. Timothy Garvey talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston, MA about the differences between the varied obesity guidelines from which a practitioner has to choose.

In part 5 of this Exclusive Interview, Dr. W. Timothy Garvey talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston, MA about obesity in children and how to treat pediatrics with limited pharmaceutical options or effective tools.

In part 6 of this Exclusive Interview, Dr. W. Timothy Garvey talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston, MA about the need for and timing of bariatric surgery.

In part 7 of this Exclusive Interview, Dr. W. Timothy Garvey talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston, MA about his opinion on the most promising weight loss medications currently in development.

In part 8, the conclusion of this Exclusive Interview, Dr. W. Timothy Garvey talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston, MA about correcting the current coding for obesity, which can impact terminology, stigmatization, insurance approvals, etc.

DEPICT-2 study of more than 800 people worldwide indicates positive results without added risk of severe hypoglycemia, but slight increase in DKA events.

The FDA approved the 90-day version of the implantable CGM Sensor.

A dual-hormone, artificial pancreas delivering rapid insulin and the drug pramlintide improved glucose management and reduced glucose variability in adults with type 1 compared to an insulin-only, first-generation artificial pancreas.